Recombinant Mouse IFN-beta protein (His Tag)
Species
Mouse
Purity
>90 %, SDS-PAGE
Tag
C-His
Activity
not tested
Cat no : Eg0660
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Mouse IFN-beta protein Ile22-Asn182 (Accession# P01575) with a His tag at the C-terminus. |
| GeneID | 15977 |
| Accession | P01575 |
| PredictedSize | 23.8 kDa |
| SDS-PAGE | kDa, reducing (R) condition |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Interferon beta (IFN-beta) is a cytokine that is naturally produced by the immune system in response to biological and chemical stimuli. It signals by binding to the heterodimeric type I IFN receptor composed of the IFNAR1 and IFNAR2 chains, and regulates the expression of a plethora of genes by means of the classical JAK/STAT and other pathways. Interferon beta (IFN-beta) has been shown in several clinical trials to have efficacy in multiple sclerosis. Interferon beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.
References:
1. M Haji Abdolvahab.et al.(2016) Int Rev Cell Mol Biol.326:343-72. 2. Revel M.et al. (2003) Pharmacol Ther.100(1):49-62. 3.Jun Yoshida.et al. (2004) Cancer Sci.95(11):858-65.